Similar articles for PMID: 27578024

Year	Number of Results
2003	5
2004	5
2005	5
2006	1
2007	3
2008	2
2009	4
2010	3
2011	1
2012	3
2013	17
2014	17
2015	24
2016	15
2017	12
2018	9
2019	4
2020	8
2021	5
2022	17
2023	6
2024	0

1

Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.

Romera I, Ampudia-Blasco FJ, Pérez A, Ariño B, Pfarr E, Giljanovic Kis S, Naderali E. Romera I, et al. Endocrinol Nutr. 2016 Dec;63(10):519-526. doi: 10.1016/j.endonu.2016.06.003. Epub 2016 Aug 28. Endocrinol Nutr. 2016. PMID: 27578024 English, Spanish.

2

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.

Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ PIO investigators. Kovacs CS, et al. Clin Ther. 2015 Aug;37(8):1773-88.e1. doi: 10.1016/j.clinthera.2015.05.511. Epub 2015 Jun 29. Clin Ther. 2015. PMID: 26138864 Clinical Trial.

3

Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials.

Romera I, Gomis R, Crowe S, de Pablos-Velasco P, Aranda U, García A, Kis SG, Naderali E. Romera I, et al. J Diabetes Complications. 2016 Nov-Dec;30(8):1571-1576. doi: 10.1016/j.jdiacomp.2016.07.016. Epub 2016 Jul 25. J Diabetes Complications. 2016. PMID: 27499456 Clinical Trial.

4

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.

Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ METSU investigators. Haering HU, et al. Diabetes Res Clin Pract. 2015 Oct;110(1):82-90. doi: 10.1016/j.diabres.2015.05.044. Epub 2015 May 29. Diabetes Res Clin Pract. 2015. PMID: 26324220 Clinical Trial.

5

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG PIO™ trial investigators. Kovacs CS, et al. Diabetes Obes Metab. 2014 Feb;16(2):147-58. doi: 10.1111/dom.12188. Epub 2013 Aug 22. Diabetes Obes Metab. 2014. PMID: 23906415 Clinical Trial.

6

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.

Araki E, Tanizawa Y, Tanaka Y, Taniguchi A, Koiwai K, Kim G, Salsali A, Woerle HJ, Broedl UC. Araki E, et al. Diabetes Obes Metab. 2015 Jul;17(7):665-74. doi: 10.1111/dom.12464. Epub 2015 Apr 15. Diabetes Obes Metab. 2015. PMID: 25772548 Clinical Trial.

7

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R. Roberts VL, et al. Clin Ther. 2005 Oct;27(10):1535-47. doi: 10.1016/j.clinthera.2005.10.017. Clin Ther. 2005. PMID: 16330290 Clinical Trial.

8

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.

Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Rosenstock J, et al. Diabetes Obes Metab. 2013 Dec;15(12):1154-60. doi: 10.1111/dom.12185. Epub 2013 Aug 22. Diabetes Obes Metab. 2013. PMID: 23906374 Clinical Trial.

9

Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.

Yoon KH, Nishimura R, Lee J, Crowe S, Salsali A, Hach T, Woerle HJ. Yoon KH, et al. Diabetes Obes Metab. 2016 Oct;18(10):1045-9. doi: 10.1111/dom.12699. Epub 2016 Jul 13. Diabetes Obes Metab. 2016. PMID: 27265507 Clinical Trial.

10

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Ridderstråle M, et al. Cardiovasc Diabetol. 2013 Sep 5;12:129. doi: 10.1186/1475-2840-12-129. Cardiovasc Diabetol. 2013. PMID: 24007456 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year